News | March 14, 2011

Company Announces 100,000th Heart Valve Implantation

March 14, 2011 – Sorin Group has reached a major milestone with the 100,000th MitroFlow Aortic Pericardial Heart Valve implantation worldwide.

Aortic valve replacement is the most effective treatment for aortic valve diseases, improving survival rates and quality of life. The pericardial valve is able to fully replace a malfunctioning or diseased aortic heart valve, offering an effective choice for patients and surgeons.

Since its introduction in Europe in 1982, the device has demonstrated excellent hemodynamic performance and proven long-term durability. Due to its design, supported by nearly 30 years of clinical use and 21 years of published long-term results, the valve is recognized by surgeons worldwide for its versatility and ease of implant, even in the most challenging anatomies.

“Our clinical experience with over 1,900 implants with the Mitroflow Aortic Pericardial Heart Valve has shown the valve’s exceptional durability, one of the longest on the market. This can be attributed to its special design, easy implantability and excellent hemodynamic characteristics. Mitroflow has provided assurance to a wide variety of patients who prefer or require biological valve implantation,” said Charles Yankah, associate professor of surgery, Charité Medical University and consultant CardioThoracic and vascular surgeon, German Heart Institute in Berlin, Germany.

For more information: www.sorin.com

Related Content

Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery | February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery | November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
Overlay Init